Report: Global hepatitis C market to witness negative compound annual growth rate of 2.1% by 2025

9 February 2017 (Last Updated February 9th, 2017 18:30)

The hepatitis C market is projected to decline from $21.7bn in 2015 to $17.5bn by 2025, according to a report by GlobalData.

Report: Global hepatitis C market to witness negative compound annual growth rate of 2.1% by 2025

The hepatitis C market is projected to decline from $21.7bn in 2015 to $17.5bn by 2025, according to a report by GlobalData.

Titled ‘Hepatitis C Virus (HCV) Therapeutics – Global Drug Forecast and Market Analysis to 2025’, the report attributes the decline to improvements in hepatitis C treatment leading to high cure rates and reduction in adverse effects in patients suffering from chronic hepatitis C infection.

The report covers the nine major markets (9MM) of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China. The hepatitis C market principally consists of direct-acting antivirals (DAAs).

"Decline in patient populations and an increase in DAA treatment rates are anticipated to reduce disease prevalence and contribution of the US in the 9MM to 48% by 2025."

Multiple pan-genotypic DAA therapy alternatives are now being introduced, which have the potential to further improve cure rates, reduce treatment duration and offer excellent efficacy and safety profiles, observes GlobalData healthcare analyst Mirco Junker, PhD.

The US was the main market for DAAs, holding a 60% share in 2015. Decline in patient populations and an increase in DAA treatment rates are anticipated to reduce disease prevalence and contribution of the US in the 9MM to 48% by 2025.

Europe’s contribution, however, is projected to increase from 20% in 2015 to 24% by 2025. The contribution from individual countries in the region is, however, expected to be highly uneven.

Low prevalence and high treatment rates in France, Germany and the UK, for example, will enable these countries to eradicate hepatitis C in the future. High prevalence in Spain and Italy, on the other hand, will increase cost burden and require expensive DAA treatments for patients.